Results 121 to 130 of about 1,804,185 (380)

Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer

Nature Communications, 2018
HIV envelope (Env) is a potential vaccine antigen and its N-glycans are part of the epitope of broadly neutralizing antibodies. Here, the authors show that glycosylation of Env from infectious virus closely matches Env from recombinant membrane-bound ...
Liwei Cao, Matthias Pauthner, Raiees Andrabi, Kimmo Rantalainen, Zachary Berndsen, Jolene K. Diedrich, Sergey Menis, Devin Sok, Raiza Bastidas, Sung-Kyu Robin Park, Claire M. Delahunty, Lin He, Javier Guenaga, Richard T. Wyatt, William R. Schief, Andrew B. Ward, John R. Yates, Dennis R. Burton, James C. Paulson   +18 more
doaj   +1 more source

Lactoferrin treatment activates acetylcholinesterase, decreasing acetylcholine levels in non‐small cell lung cancer (NSCLC) cell culture supernatants, inhibiting cell survival

FEBS Open Bio, EarlyView.
Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel, Caroline Wozniak, Aya Sabri, Ben Haddad, Brooke Lopo, Alvaro Cobos, Sarah Sarofim, Jeffrey Guthrie, Deborah Heyl, Hedeel Guy Evans   +9 more
wiley   +1 more source

Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming

npj Vaccines
Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens.
Allan C. deCamp, Martin M. Corcoran, William J. Fulp, Jordan R. Willis, Christopher A. Cottrell, Daniel L. V. Bader, Oleksandr Kalyuzhniy, David J. Leggat, Kristen W. Cohen, Ollivier Hyrien, Sergey Menis, Greg Finak, Lamar Ballweber-Fleming, Abhinaya Srikanth, Jason R. Plyler, Farhad Rahaman, Angela Lombardo, Vincent Philiponis, Rachael E. Whaley, Aaron Seese, Joshua Brand, Alexis M. Ruppel, Wesley Hoyland, Celia R. Mahoney, Alberto Cagigi, Alison Taylor, David M. Brown, David R. Ambrozak, Troy Sincomb, Tina-Marie Mullen, Janine Maenza, Orpheus Kolokythas, Nadia Khati, Jeffrey Bethony, Mario Roederer, David Diemert, Richard A. Koup, Dagna S. Laufer, Juliana M. McElrath, Adrian B. McDermott, Gunilla B. Karlsson Hedestam, William R. Schief   +41 more
doaj   +1 more source

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group [PDF]

, 2010
The Global HIV Vaccine Enterprise convened a meeting of a Working Group in July 2009 to discuss recent progress in rational design of the components of an HIV vaccine, such as inserts, vectors and adjuvants,and in understanding antigen processing and ...
John Mascola, Ralph Steinman, Richter C. King, the Working Group convened by the Global HIV Vaccine Enterprise   +3 more
core   +3 more sources

Neutralizing Antibody Response and SARS Severity

Emerging Infectious Diseases, 2005
Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks.
Ho, Mei-Shang, Chen, Wei-Ju, Chen, Hour-Young, Lin, Szu-Fong, Wang, Min-Chin, Di, Jiali, Lu, Yen-Ta, Liu, Ching-Lung, Chang, Shan-Chwen, Chao, Chung-Liang, King, Chwan-Chuen, Chiou, Jeng-Min, Su, Ih-Jen, Yang, Jyh-Yuan   +13 more
openaire   +5 more sources

Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natalizumab (NTZ) is a highly effective therapy for multiple sclerosis (MS); however, its use is limited by the risk of a rare potentially severe opportunistic brain infection, progressive multifocal leukoencephalopathy (PML). Alternative dosing strategies are evaluated to reduce PML risk while still maintaining efficacy, which ...
Regina Berkovich, Tilman Schneider‐Hohendorf, Eric Baetscher, Evan L. Riddle, Marie Deffner, Emily Katsnelson, Janine Ferrant‐Orgettas, Julie Czerkowicz, John Anderson, Susan E. Goelz, Nicholas Schwab   +10 more
wiley   +1 more source

Use of a lambda gt11 expression library to localize a neutralizing antibody-binding site in glycoprotein E2 of Sindbis virus [PDF]

, 1991
The Sindbis virus envelope contains two species of integral membrane glycoproteins, E1 and E2. These proteins form heterodimers, and three dimeric units assemble to form spikes incorporated into the viral surface which play an important role in the ...
Strauss, James H., Wang, Kang-Sheng
core   +1 more source

In vivo Neutralization of Pro-inflammatory Cytokines During Secondary Streptococcus pneumoniae Infection Post Influenza A Virus Infection [PDF]

, 2019
An overt pro-inflammatory immune response is a key factor contributing to lethal pneumococcal infection in an influenza pre-infected host and represents a potential target for therapeutic intervention.
Boehme, Julia D., Bruder, Dunja, Christen, Henrike, Guzmán, Carlos A., Hernandez-Vargas, Esteban A., Kershaw, Olivia, Schreiber, Jens, Sharma-Chawla, Niharika, Stegemann-Koniszewski, Sabine   +8 more
core   +1 more source

Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection

medRxiv, 2020
Most individuals infected with SARS-CoV-2 develop neutralizing antibodies that target the viral spike protein. Here we quantify how levels of these antibodies change in the months following SARS-CoV-2 infection by examining longitudinal samples collected
K. H. Crawford, A. Dingens, Rachel T. Eguia, C. Wolf, Naomi C Wilcox, J. Logue, Kiel Shuey, A. Casto, B. Fiala, Samuel P Wrenn, D. Pettie, N. King, H. Chu, Jesse D. Bloom   +13 more
semanticscholar   +1 more source

Growth Differentiation Factor 15 Elevation in the Central Nervous System Is Associated With Failure to Thrive in Alexander Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Alexander disease (AxD) is a severe neurodegenerative disorder caused by gain‐of‐function mutations in the gene for GFAP, which lead to protein aggregation and a primary astrocytopathy. Symptoms vary, but failure to thrive (FTT) and frequent emesis are common and cause significant morbidity. Here we investigate GDF15, a member of the
Tracy L. Hagemann, Michelle M. Sonsalla, Cora Luzinski, Fernando Zacahua, David A. Harris, Dudley W. Lamming, Albee Messing   +6 more
wiley   +1 more source